Morgan Stanley has been forced to delay the flotation of ProStrakan due to difficulties in pricing the fledgling Scottish pharmaceuticals firm.

Warburg Pincus, the New-York based private equity firm backing ProStrakan, has already had to cut the offer price by around 25%.